Bempikibart (ADX-914) is a human anti-IL-7Rα antibody that blocks the IL-7 and TSLP pathways, which have been implicated in driving T cell-mediated pathological processes in autoimmune diseases.

The Food and Drug Administration (FDA) has granted Fast Track designation to bempikibart for the treatment of alopecia areata (AA).

Discover management strategies for alopecia areata, from anti-inflammatory diets to stress reduction techniques that can help ...

Medically reviewed by Susan Bard, MD Alopecia areata is a common hair loss condition. It affects people of all ages, races, ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, ...

Gluten might appear harmless, but for some individuals, it can silently provoke significant health problems. Often lacking ...

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported ...

Metformin is a drug used to treat type 2 diabetes mellitus. While some may notice fallout or thinning when taking this ...

Raechetta Thompson's traveling salon is providing a valuable service for individuals dealing with alopecia and other forms of ...

When it comes to the world of hair loss, it’s no question that the amount of information out there can feel extremely ...

“Our CB-SCs can target different compartments of the immune system, educating and correcting their dysfunctions at a fundamental level,” says Dr. Zhao. “This therapy has the potential to revolutionize ...

("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced ...